Genomic Vision: The Performances of the FSHD Diagnostic Assay Presented at the 2018 International FSHD Research Conference (I...
June 11 2018 - 1:45AM
Business Wire
- The team of Prof. Frank Baas (Leiden
University Medical Centre) presented the results of a study
conducted on 80 patients
- The results demonstrate an improvement
of the FSHD detection thanks to molecular combing compared to the
common Southern Blot technology
Regulatory News:
Genomic Vision (FR0011799907 – GV) (Paris:GV), a company
specializing in the development of diagnostic tests for the early
detection of cancers and hereditary diseases, and applications for
life sciences research, today announces that Prof. Frank Baas
(Leiden University Medical Centre), a worldwide recognized key
opinion leader on FSHD (Facioscapulohumeral Muscular Dystrophy),
has presented the results of an efficacy study of the FSHD
diagnostic assay based on the FiberVision® platform in comparison
to the traditional technology of Southern blot. This presentation
was held last weekend in Las Vegas at the 2018 FSHD International
Research Conference (IRC).
During this event which gathered the most prestigious key
opinion leaders on FSHD, the team of Prof. Baas presented the
results of a comparison study led in Leiden with two groups of 40
individuals. Entitled « Evaluation of FSHD1 testing in
diagnostics using FiberVision® platform based on Molecular Combing
technology », the study demonstrated that the molecular
combing technology allowed a 100 % correct classification of
individuals not affected by the disease. The FSHD diagnostic assay
of Genomic Vision also allowed to precisely quantify the D4Z4
repeated sequence involved in the pathology in 95% of the samples
of affected patients whose complete analysis was conducted.
Aaron Bensimon, cofounder and CEO of Genomic Vision,
declared: « While our FSHD diagnostic array is already
used by several reference hospital centers, such as La Timone in
Marseille, we are extremely proud that its performances are
highlighted. Presented during the prestigious IRC, the performance
study comparing our technology to Southern blot demonstrates the
sharp precision of molecular combing and positions it as a new
standard for the FSHD detection while deepening the knowledge and
the understanding of the genetic events of the
pathology. »
Facioscapulohumeral muscular dystrophy (FSHD) is the third most
prevalent muscular hereditary myopathy worldwide. This genetic
disease is characterized by atrophy and weakness of the face,
shoulders, and ambulatory muscles. There is great variability in
the clinical severity, from a severe infantile form to individuals
who remain asymptomatic throughout most of their life. It is
estimated that this autosomal dominant disease affects 1 in 10,000
to 1 in 20,000 people. Today there are 870,000 individuals
worldwide affected by FSH, a number that could be significantly
higher given the undiagnosed cases. About 70% of FSHD patients
inherit the disease from a parent, while 30% of the cases are
sporadic and associated with de novo mutations.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs. The Company
develops a robust portfolio of diagnostic tests (breast, ovarian
and colorectal cancers, myopathies) and analysis tools (DNA
replication, biomarkers discovery, gene editing quality control).
Based near Paris, in Bagneux, the Company has approximately 50
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907). For further information, please visit
www.genomicvision.com
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 28, 2017, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180610005063/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorUlysse
CommunicationPress RelationsBruno Arabian, +33 1 42 68
29 70barabian@ulysse-communication.comorNewCapInvestor
RelationsDušan Orešanský / Emmanuel Huynh+33 1 44 71 94
92gv@newcap.eu
Genomic Vision (EU:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genomic Vision (EU:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024